Researchers at New York University have devised a mathematical approach to predict the structures of crystals—a critical step in developing many medicines and electronic devices—in a matter of ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

AbbVie in September said another Cerevel drug candidate, tavapadon, met the primary endpoint in a pivotal Phase 3 study in the neurodegenerative disorder Parkinson's disease. AbbVie shares, which hit ...

AbbVie said its recently acquired emraclidine drug candidate for schizophrenia missed the key goal in a pair of mid-stage studies, sending the biopharmaceutical company's shares down more than 10% in ...

AbbVie (ABBV) shares dropped 11% premarket as late-stage trials for schizophrenia drug emraclidine did not meet primary ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

a Represents net earnings attributable to AbbVie Inc. Acquisition and integration costs primarily reflect integration costs related to the Allergan acquisition, including a one-time gain ...

a Represents net earnings attributable to AbbVie Inc. Acquisition and integration costs primarily reflect integration costs related to the Allergan acquisition, including a one-time gain of $169 ...